Risvodetinib demonstrated to be safe and well-tolerated with preliminary clinical benefits Risvodetinib demonstrated to be the first treatment to reduce alpha-synuclein pathology, widely recognized as ...
ATLANTA and BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- ABLi Therapeutics ("ABLi"), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosine ...
ATLANTA and BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- ABLi Therapeutics (“ABLi”), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosine ...
Opportunity to utilize time-to-delay of levodopa/carbidopa initiation as an endpoint to measure trial success, which Company believes is a direct measure of disease-modification ATLANTA and BOSTON, ...
The MarketWatch News Department was not involved in the creation of this content. ATLANTA and BOSTON, Sept. 15, 2025 (GLOBE NEWSWIRE) -- ABLi Therapeutics ("ABLi"), a biotechnology company developing ...
Hosted on MSN
ABLi releases Phase II risvodetinib results for PD
ABLi Therapeutics has announced final outcomes from its Phase II 201 Trial of risvodetinib in untreated Parkinson’s disease (PD), achieving the primary endpoint of tolerability and safety. The ...
ATLANTA and BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- ABLi Therapeutics ("ABLi”), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosine ...
ATLANTA and BOSTON, May 06, 2026 (GLOBE NEWSWIRE)-- ABLi Therapeutics ("ABLi”), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosine ...
(MENAFN- GlobeNewsWire - Nasdaq) Lead candidate Risvodetinib (ABLi-148009) is an oral, once-daily, potent, brain-penetrant, selective c-Abl kinase inhibitor that is the first to drive clearance of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results